8x8 Inc vs Novavax Inc — how do they compare? 8x8 Inc trades at $1.93 (market cap $279.31M), while Novavax Inc trades at $8.27 (market cap $1.39B). The key difference: Novavax Inc is far larger — about 5× 8x8 Inc's market cap, and Novavax Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | NVAX | |
|---|---|---|
Market Cap | $279.31M | $1.39B |
Sector | Technology | Health |
52-Week High | $2.76 | $11.19 |
52-Week Low | $1.59 | $6.22 |
Enterprise Value | $556.99M | $890.94M |
Signals from Pluang's Aura AI — not financial advice
EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.
Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Trailing returns across standard periods
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →